Vaccitech is a clinical stage T cell immunotherapy and vaccine company developing products to treat and prevent infectious disease and cancer
The company’s proprietary heterologous prime-boost platform comprises Chimpanzee Adenovirus Oxford (ChAdOx) and Modified Vaccinia Ankara (MVA), two non-replicating viral vectors which safely mimic viral infection in human cells and elicit high magnitude, durable, targeted CD8+ and CD4+ T cell responses and antibodies to clear foreign pathogens and tumours.
The platform was licensed from the prestigious Jenner Institute for vaccine research at the University of Oxford, which dedicated over 20 years of research to identify and refine the optimal method for CD8+ T cell induction in humans. This platform has generated a robust, largely immunotherapeutic pipeline of six clinical product candidates for infectious disease and cancer indications, four of which are in co-development with partners and external funding.
Vaccitech is backed by leading investment institutions, including GV (formerly Google Ventures), Sequoia Capital China, Liontrust (formerly Neptune), Korea Investment Partners and Oxford Sciences Innovation.